Greetings, and welcome to the Corbus Pharmaceuticals Quarterly Update Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Ted Jenkins, Senior Director, Investor Relations and Corporate Communications. Thank you. You may begin.

Thank you, Donna. Good morning, everyone, and thank you for joining us for the Corbus Pharmaceuticals fourth quarter and 2018 yearend update conference call and webcast. At this time, I'd like to remind our listeners that remarks made during this call may state management's intentions, hopes, beliefs, expectations or projections of the future. These forward-looking statements that involve risks and uncertainties. Forward-looking statements on this call are made pursuant to the Safe Harbor provisions of the Federal Securities Laws. These forward-looking statements are based on Corbus' current expectations, and actual results could differ materially. As a result, you should not place undue reliance on any forward-looking statements. Some of the factors that could cause actual results to differ materially from those contemplated by such forward-looking statements are discussed in the periodic reports Corbus files with the Securities and Exchange Commission. These documents are available in the Investors section of the company's website and on Securities and Exchange Commission's website. We encourage you to review these documents carefully. Joining me on the call today is Yuval Cohen, our Chief Executive Officer; Sean Moran, Chief Financial Officer; Craig Millian, our new Chief Commercial Officer and Barbara White, Chief Medical Officer. It's now my pleasure to turn the call over to Yuval Cohen.

Thank you, Ted. Good morning, and thank you everyone for joining us today. My name is Yuval Cohen. I am the CEO of Corbus. 2018 was a transformational year for Corbus and I want to take the opportunity today to review some of our key achievements, provide an update on our clinical programs and walk you through some of the key themes for 2019. I will then provide a financial update before I will open the call for your questions. In 2018, we made significant progress towards our mission of becoming the leading pharmaceutical company in the treatment of inflammatory and fibrotic diseases by targeting the endocannabinoid system also known as the ECS, a master regulator of inflammation and fibrosis in the body. Our vision is important as it underpins everything we do and it speaks to our long-term belief that the cannabinoid biology will become one of the hallmarks of medical advances in this coming decade. Furthermore as a pioneer in the development of small molecules, that binds the cannabinoid receptors we believe that Corbus is uniquely positioned to become the leading source of endocannabinoid system targeting therapeutic. Stepping back, cannabinoids is a term that is attracting a lot of interest and I'd like to briefly remind you all of how Corbis fits into this landscape. Endocannabinoid are the body's own endogenous cannabinoids signaling molecule that play a role in keeping our body healthy. Vital cannabinoids are chemicals found in the Cannabis plant such as THC and CBD. They are extracted from the plant in our pool of therapy for significant medical problems such as severe [indiscernible] epilepsy, nausea and vomiting and people undergoing chemotherapy and the loss of appetite and weight loss in people's treating with cancer, but importantly our compounds are neither endocannabinoid or phytocannabinoids. Our compounds…

Thanks Yuval. Let me start by saying I’m thrilled to join Corbus at such an exciting time for the company. As a bit of background, I joined Corbus from EMD Serono where I most recently served as Senior Vice President and Head of U.S. Neurology and Immunology. Prior to that, I held a number of commercial leadership roles at Vertex, Pfizer and Sanofi. What attracted me to Corbus was first of all Yuval and the other talented members of the team, all of whom share an inspiring vision and a commitment to excellence. I've only been on board for a short time but I've already witnessed the truly collaborative team oriented environment that's been cultivated here and it's a true source of strength for the company. I'm also very excited about the science underpinning Corbus’s work. Synthetic cannabinoid development presents a significant opportunity. As Yuval noted, this has the potential to be a truly groundbreaking therapeutic area in the coming years and Corbus is at the forefront of developing novel synthetic cannabinoid medicines. I'm energized and excited to be joining such a talented team and I look forward to help building the commercial strategy and infrastructure as lenabasum moves towards the completion of key registrational studies in 2020, while I'm currently head down as I get fully up to speed in my new role, I do look forward to meeting many of you in the coming months. And with that, I'd like to turn the call back over to Yuval.

Thank you, Craig. Craig’s appointment is an important milestone for Corbus and we're confident that Craig's experience and leadership will drive a successful launch for lenabasum which we expect to be in 2021. We'd like to now provide an update on our clinical pipeline starting with lenabasum. With that let me turn the call over to Barbara to provide an update on our clinical pipeline. Barbara?

Thank you, Yuval. Lenabasum, a CB2 agonist is our lead clinical asset. Lenabasum is currently being evaluated in Phase 3 studies for systemic sclerosis and dermatomyositis and in Phase 2 studies for cystic fibrosis and lupus. Patient enrollment and dosing in our Phase 3 RESOLVE-1 study for systemic sclerosis remain on track and we anticipate the last patients by May. We are on track for study completion in the first half of 2020 and we anticipate NDA submission at the end of 2020. We are optimistic that lenabasum has the potential to provide clinical benefit to patients with systemic sclerosis. Our optimism is based on the mechanism of action of the drug, benefitting animal models of the disease, consistent improvement in multiple efficacy outcomes in the double-blind placebo controlled Phase 2 study of lenabasum and systemic sclerosis as well as its open label extension. And evidence of improvement of inflammation and fibrosis biomarkers in skin of study subjects, we also remind you that lenabasum has orphan drug and fast track designations for treatment of systemic sclerosis with the FDA and orphan drug designation for treatment of systemic sclerosis with EMA. Our Phase 3 DETERMINE study is a registrational study testing safety and efficacy of lenabasum as a treatment for dermatomyositis, our second potential rare autoimmune disease indication. Corbus has received input on study design from regulatory authorities in the U.S., Europe and Japan. This study is enrolling subjects. It will be the largest interventional study to date in dermatomyositis. We will keep you informed as key milestones occur. Our Phase 2 study of lenabasum evaluating effects on the rate of pulmonary exacerbation in patients with cystic fibrosis is also ongoing and on track for data in 2020. The study is enrolling patients 12 years of age and above at high risk for pulmonary exacerbation without regard to CFTR mutation, pulmonary pathogens or background medications. This study is funded in part by a Development Award for up to $25 million from the Cystic Fibrosis Foundation to follow the $5 million award we received in 2015. Lenabasum has orphan drug and fast track designations for treatment of cystic fibrosis with the FDA and orphan drug designation for treatment of cystic fibrosis with EMA. The NIH conducted lupus clinical study is progressing and we look forward to its completion. With that, I'll turn it back to Yuval.

Thank you, Barbara. Lenabasum presents a significant market opportunity for these three initial indications with potentially up to $5 billion and 350,000 patients in the seven major markets. This includes approximately $1.4 billion to $2.2 billion in peak annual potential sales for systemic sclerosis with 200,000 patients in the U.S., Europe and Japan, approximately $1 billion to $2 billion dollars in peak annual potential for dermatomyositis with approximately 80,000 patients in the U.S., Europe and Japan. Approximately $700 million to $1 billion peak annual potential sales for cystic fibrosis with approximately 75,000 patients in the U.S. and Europe. Turning to CRB-4001, we continue to plan initiating a Phase 1 study of CRB-4001 in 2019 expected to be followed by an NIH National Institute of Health sponsored Phase 2 study in NASH. CRB-4001 is a second generation inverse agonist targeting peripheral organ fibrosis with strong preclinical data. In addition to lenabasum and CRB-4001, we expect to start one or two new clinical programs each year based in large part on the development and progression of drug candidates from our internal library beginning in 2020. We are very excited about the potential for our robust pipeline and we look forward to providing an update with the first candidate or candidates we select later this year. Now let me briefly comment on our financial position. As we enter 2019, we have a strong balance sheet to help drive our operations through pivotal Phase 3 data for lenabasum. We ended 2018 with approximately $42 million in cash but this figure does not include the $27 million Kaken upfront licensing payment nor does that include the proceeds from our $40 million recent public offering. As a reminder, our partnership with Kaken alone will provide up to an additional $173 million upon achievements of certain regulatory,…

Thank you. At this time, we will be conducting a question-and-answer session. [Operator Instructions] Our first question is coming from Liisa Bayko of JMP Securities. Please proceed with your question.

Hi, good morning. How are you?

Good morning, Liisa.

I want to welcome Craig to the team and ask you kind of what are your plans you see now in commercialization, what are some of the key activities you'll be doing and then maybe you can comment a little you throw out some numbers for market size, which implies some idea about kind of price ranges may be can ballpark that for us as well. Thank you.

Yes sure. Hi Liisa, thank you for the welcome. I think I’ll start by getting out and starting to meet with some of our KOLs and patient advocates and really getting grounded in the science and the current treatment patterns and the disease. We'll continue to define the commercial opportunity and certainly builds on our market research, I think we want to continue to Yuval gave a range of forecasts, I think we'll continue to refine that. I think it's a really good start. Obviously, we'll be building out some initial launch plans and starting to think about a range of options in terms of our go-to-market strategy for our different markets and our different indications. We'll be thinking about our value proposition and thinking about the possibilities of our data and our label and the implications for that. So we'll want to start thinking about that from a payer perspective. And obviously, we'll start to identify some key capabilities and gaps in our staffing that we'll want to start to fill with some key hires. So those are all some of the things I'll be focused on. The numbers that Yuval quoted were from a fairly robust assessment, commercial assessment that was done by Health Advances completely kind of objective piece of analysis that they did and was based on both published data as well as some primary research they conducted with KOls and payers in the U.S. and in Europe. I don't want to get into the specifics of the pricing at this point. I would say I think it was a fairly reasonable assumption that was built in, in terms of both the pricing assumption as well as the penetration within the different indications to come up that range. But again I think it's a little premature at this point. So we'll continue to dig into that and refine our assumptions as I mentioned and continue to acquire data and market research to validate those and will share those in due time.

Okay, great. Thanks. And then just one question maybe for Barbara, for your kind of foray into NASH. Can you maybe talk about your mechanism, is it primarily surrounding the kind of inflammatory component or do you see sort of other contributions obviously in the NASH as a complex disease with multiple different ways to target either through fat fibrosis, through inflammation where does your compound play?

Liisa, thank you so much for that question. CRB-4001 is a CB1 inverse agonist. That means that in inhibits CB1 and by doing that, we will have effects on multiple pathways that seem to be involved in the pathogenesis of NASH. First, we would anticipate having beneficial effects on metabolic pathways and it's been shown that inhibiting CB1 can help with insulin resistance with glucose metabolism, energy metabolism. It helps with life of Genesis, so it helps restore a number of the underlying metabolic abnormalities that many patients with NASH have. Secondly, it's also been shown to have effects on both inflammation and fibrosis which are the aspects of the disease pathogenesis that drive the initial aspects of liver damage and then the final cirrhosis that can lead to the need for a liver transplant or even Hepatocellular carcinoma. So targeting CB1 to inhibit it has the potential to affect those three very important pathways, metabolic abnormalities, inflammation and fibrosis. And we think that's a therapeutic edge, indeed Johnson & Johnson also has put effort into targeting CB1 inhibiting CB1 in the treatment of NASH, they're doing it with a monoclonal antibody which we think also is extra validation of the potential clinical benefit of this approach.

Thanks a lot, guys.

Thank you. Our next question is coming from Brian Abrahams of RBC Capital Markets. Please proceed with your question.

Hey guys, thanks so much for taking my questions and congrats on all the progress.

Thanks Brian.

My first question is around the ongoing clinical studies with the RESOLVE systemic sclerosis study nearing completion of enrollment, I was wondering if you could maybe speak a little bit I guess qualitatively about the types of patients who've entered that study and the work that you've done to ensure that it's a refined population and you've kind of eliminated the chance that patients with burned out disease are entering the study and I guess as a corollary to that. I know it's kind of early days in the dermatomyositis Phase 3 but wondering if you could maybe talk a little bit about how the initial set up there is going? The types of patients and the mix that you're getting enrolling in that study relative to expectations and whether you have any sense as to what this initial enrollment trajectory might mean for potential timelines there? And then I have a couple of follow-ups. Thanks.

Certainly Brian, thanks. The first part of that just nudge me about it. So first of all regarding the SSC Phase 3 study, that study and all the studies were all blinded to treatment assignment. So all I can say is what does the group in general look like. And it looks like what we expected and will look like many other studies that have been done in patients with diffused cutaneous systemic sclerosis. So both in terms of age, gender, we've covered many geographies U.S., many European countries, Japan, South Korea, Australia we expect to have very representative group of patients so that clinical benefit can be determined again in a representative group of patients. I would point out that there that we have made reasonable attempts to identify patients who could benefit from treatments. And that's where I'd like to couch our patient selection folks who could benefit from treatment. And we've selected patients with who have disease duration of no more than three years without any other requirement because in general they’re thought to be able to get to have a need for treatment to be able to benefit whether radiance in skin, lung, joints whatever they're multiple ways that those patients can benefit and we will capture. Similarly, we allow patients who have disease duration for three to six years, if they have a certain level of skin involvement. So that again there's at least that component of the disease is measurable, improvement would be measurable. So we're very, very comfortable with the type of patients that we've enrolled. There's been nothing unexpected. And we look forward to seeing the results and completing that enrollment very soon. In terms of dermatomyositis study, again it's an important question. How do you know you've got patients represent those who have the disease and who can benefit. First of all those inclusion criteria that we've selected allow us to include patients who represent the breadth of the disease, those with classic dermatomyositis that is muscle involvement and some skin variable degrees of skin but very definite muscle involvements through folks who have very definite skin involvement and minimal if any clinically apparent muscle involvement. So that whole range has included the outcome that we have, the total improvement score is adequate to measure clinical benefit in that range of patients, we have selected patients who have to have certain degrees of disease activity and that is based upon the types of involvement they have. First of all the physician has to say they have active disease, so they have to sort of put out these papers, this patient is active which is almost as good as anything as well as they have to have a certain degree of muscle involvement, or certain degree of skin involvement, have to have a certain degree of global abnormalities. So again, I'm quite confident we've got the right patients, the right outcome and the right inclusion criteria.

That's very helpful, Barbara, thanks. And then we noticed that the structure of CB2 was recently published, just wondering how that might further facilitate the interrogation and development of additional CB2 and CB1 targeted treatments within the compound library that that you now have as you look to bring some of these compounds forward next year. We'd love to hear about the types of compound profiles that you might be looking to pursue there?

Well, thank you. I'm just so happy to have that question. First of all about the crystal structures. And I would say actually In silico model of how our CRB-4001, our CB1 inverse agonist actually binds to CB1 has been published already and we will do similar In silico models for our pipeline candidates as they move along because it will help inform us about a number of potential properties, it’s just a part of the data that we are building as experts in this field, the types of interactions we want with particular regions or particular parts of binding regions. And we will do that for all of the compounds that we move forward into the clinic as part of our interrogation of their potential benefit. It allows us to actually tweak molecules as well as we develop our own set of internal compounds by determining just what we want to engage or not engage. So very useful information for us. And we are using it currently and we'll continue to use it in silico modeling.

That's really helpful. Last question from me maybe on the commercial front perhaps a question for Craig. You spoke about some of the initial market oriented activities that you'd be pursuing this year. How should we think about as this commercial build-out and strategy sort of takes shape and new hires come on board, the potential impact through the cadence of SG&A expenses maybe over the course of this year as the year progresses and then in subsequent years? Thanks.

Hey Brian, Sean Moran here. So we put out guidance for the cash resources we have it's over $100 million. So we are funded through data into the fourth quarter of 2020. So it covers all of those activities that Craig will be undertaking.

Thanks so much.

Yes, I think for this year there'll be primarily strategic activities and fairly minimal amounts of hiring. Obviously, the cadence of hiring as we get the data out next year as we approach filing our NDA and those things will pick up but not so much this year.

Thanks so much.

[Operator Instructions] Our next question is coming from George Zavoico of B. Riley FBR. Please go ahead with your questions.

Thanks. Good morning everyone and welcome Craig to Corbus Pharmaceuticals. Quick question about the cocaine and its responsibilities in Japan and new responsibilities there and when we might expect the first milestones including whether you anticipate any clinical trials that might have to be done specifically in Japan and how much, I guess the question basically is how much responsibilities Kaken actually have in Japan in overseeing both the development, the regulatory pricing et cetera there?

Hey George, it's Yuval.

Hi Yuval.

It’s wonderful to see you last week by the way. Kaken is our partner in Japan. On a very simplistic basis, our responsibility is to wrap up the systemic sclerosis study in Japan. Remember we have I think 10 Japanese clinical sites as well as obviously undertake the upcoming dermatomyositis study, Japanese study has already started elsewhere but not in Japan. So in Kaken’s responsibilities, regulatory responsibilities they will be our liaison and in fact represent us from now on with PMDA end of course commercial responsibility. That means negotiating pricing with the Japanese authorities as well as going out there and actually marketing and selling the drug. In terms of the milestones, they are of course confidential but George you should think about them as fairly standard. They revolve regulatory milestones, you can probably guess what those are, commercialization milestones and sales milestones very, very standard for this type of deal.

And there's a set of milestones apply both to the systemic sclerosis and dermatomyositis individually and parallel?

The deal in Japan is for just Japan which is interesting and just for systemic sclerosis and dermatomyositis, yes the answer is yes.

Okay. Thanks for that. And with regards to NASH, you mentioned that it’s NIH sponsored the first trial. How do you expect to transition from NIH sponsorship or when, I suppose in the course of the clinical event with transition from NIH sponsorship to Corbus sponsorship?

So I think that it is again, I view it as a very tight partnership with the NIH. We will do typical Phase 1 testing, when we have the typical Phase 1 data available, we’re working in collaboration with the NIH to develop the design of the next study or studies which will look at blood-brain barrier penetration and we'll also look at a number of biomarkers and perhaps even some liver imaging in patients with metabolic syndrome and with NASH. So those designs are not complete but it will be done in very close discussions with the NIH. Thereafter it's entirely up to Corbus what we decide to do. So think of the NIH as extremely helpful in the interlude in determining impact on biomarkers in blood-brain barrier penetration.

But it'll be NIH money they will run the first trial or Corbus?

We will run and pay for the Phase 1 study [indiscernible] they will run and look after and pay for internal projects the NIH, it's been a long-term interests of Dr. George Kunos, they will do the study of the biomarkers in the patients -- Phase 2 patients with NASH metabolic syndrome.

So it’s a shared funding in other words you both have defined responsibilities that you will be paying for that right?

So for the Phase 1, George it's on our dollar and of course the nice thing about Phase 1 is that they're very affordable. And then for the first in-patient Phase 1b, Phase 2a, the only obligation we have is to supply the drug for the NIH.

Okay that's good. That's a good arrangement.

I'm very happy with it.

Yuval, when you mentioned your market sizes, you talked about systemic sclerosis for example in very general terms and yet the trial is really diffused cutaneous. So can you break down a little bit, what proportion of the total would you call systemic scleroderma eligible patient population in general and which ones are actually eligible for the trial and eligible perhaps once it's approved for that indication?

I'm going to handle that. This is Barbara.

Thanks Barbara.

The proportion of diffused cutaneous systemic sclerosis varies from study to study but I think 45% as reasonable -- as a reasonable ballpark range. In terms of what the label will say, don’t forget that's important. We don't have a label yet. You're absolutely correct that the study population patients with diffused cutaneous systemic sclerosis, I do not know if the label will say systemic sclerosis or diffused cutaneous systemic sclerosis. So I'm going to leave it at that.

So in other words, each one of these trials has a defined pre-specified subgroups to take a look at that will define what the label eventually will say based on obviously the results for each of the subgroups. Is that fair to say for both scleroderma and DM?

I'm sorry. Would you mind just repeating that, George?

Well, the question is whether you have pre-specified subgroups within the broader systemic sclerosis and dermatomyositis populations. And depending on those subgroups, some might perform better than others and that might inform what the label will say eventually?

No, I'm going to say that there are always subgroup analysis.

It’s right, okay, good.

And that there you should expect the same with ours. I'm not going to speculate what the label would say at this time.

Yes, of course that's going to depend very much on the results of course.

And I did want to point out what is the difference for folks that might not know, what's the difference between diffused cutaneous systemic sclerosis and limited cutaneous systemic sclerosis. It's really defined clinically by what parts of the body the skin, the physician thinks the skin is second, in diffused cutaneous systemic sclerosis it’s upper arms, upper legs or trunk. They have to be involved and in limited less so. So for example, if the physician thinks that the skin thickening stops just below the elbow that would be limited. If the physician thinks the skin thickening extends just above the elbow, that would be diffused and the trunk.

One thing, I'll just add in terms of the market assessments that Yuval referenced. We did take into consideration, penetration rates and based on disease severity diffused is first limited. So we did actually even in this piece of research, look at different segments and assigned penetrations accordingly. Again we don't know ultimately what the label will be and what the data will readout but fairly reasonable assumptions, I think for this point in time.

Okay. Thanks and a final question regarding your 600 plus compound library. Maybe this is part of the commercial strategy for a question for Craig. I mean there's a lot of opportunities there more than likely too much so perhaps for a company of your size. Is there a licensing strategy that's going to be part of the commercial strategy?

George, let me embrace that one with both arms. The answer is resoundingly yes. If you think about it, our vision really is to become the go to company for these synthetic rationally designed compounds that bind to endocannabinoid receptors. Some diseases make perfect sense for us to go out and commercialize and market ourselves particularly rare diseases but there are many other inflammatory diseases fibrotic diseases where it makes perfect, perfect sense to actually partner with a big pharma. What I'd like to emphasize to you and overall audiences is our conviction that this coming decade will be a decade where most perhaps even all Big Pharma will embrace cannabinoid biology. We’re already seeing that, in that case each Big Pharma has a choice, they can either develop their own cannabinoids which will be expensive, lengthy, cumbersome or they could partner with the leading company that has I believe achieved a really unique position almost a dominating position around our understanding of the biology, the depth of our pipeline, our medicinal chemistry capabilities and also our patent strategy. I think the latter makes much more sense.

And then to that point, I presume that you're still growing the library?

That is a very safe assumption.

Okay, great. Thank you very much.

Thank you. This brings us to the end of today's question-and-answer session. Corbus Pharmaceuticals would like to thank you for your interest in today's conference. You may disconnect your lines at this time and have a wonderful day.